Cytotoxic antibodies to natural killer cells in systemic lupus erythematosus

Rook, Alain H.; Tsokos, George C.; Quinnan, Gerald V.; Balow, J E; Ramsey, Keith M.; Stocks, Naomi I.; Phelan, Michael A.; Djeu, Julie Y.

doi:10.1016/0090-1229(82)90229-x

Cited by 21 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A reduced number of NK cells and impaired NK cell activity was identified in a subset of SLE and RA patients (14, 15). Furthermore, the existence of autoantibodies to NK cells, found in patients with SLE (16), was reported to be associated with impaired NK cell activity (17). From this viewpoint, our findings indicate that KIR2DL would be one of the target molecules for anti–NK cell autoantibodies.…”

Section: Discussionmentioning

confidence: 99%

Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases

Matsui¹,

Otsuka²,

Maenaka³

et al. 2001

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective To investigate the existence of autoantibodies to killer immunoglobulin‐like receptors (KIRs), especially p58.1 (KIR2DL1) and p58.2 (KIR2DL3), in patients with systemic autoimmune diseases. Methods Sera from 30 patients with systemic lupus erythematosus (SLE), 30 patients with rheumatoid arthritis (RA), 22 patients with Behçet's disease, and 20 healthy control subjects were tested for anti‐p58.1 and anti‐p58.2 antibodies by Western blot analysis using recombinant p58.1 and p58.2 proteins. Furthermore, clinical features and laboratory data were compared between the anti‐p58.1/58.2 antibody–positive and –negative patients. Results Anti‐p58.1 antibodies were detected in 7 (23.3%) of the 30 patients with SLE, 9 (30%) of the 30 patients with RA, and 6 (27.3%) of the 22 patients with Behçet's disease. Anti‐p58.2 antibodies were detected in the same 22 patients who were positive for the anti‐p58.1 antibodies. None of the serum samples from the healthy donors were positive for antibodies to the recombinant p58.1 or p58.2 molecules. Compared with the anti‐p58.1/58.2 antibody–negative patients, the anti‐p58.1/58.2 antibody–positive patients had significantly elevated levels of serum IgG in all 3 diseases tested, an accelerated erythrocyte sedimentation rate in RA and SLE, and decreased white blood cell counts in RA. Conclusion This report is the first to describe the presence of autoantibodies to KIR2DL (p58.1 and p58.2) in the sera of patients with systemic autoimmune diseases. Considering the correlation with several clinical features, these autoantibodies may be involved in the pathologic process of the autoimmune diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases

Matsui¹,

Otsuka²,

Maenaka³

et al. 2001

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…However, the levels of immune complexes (Calder et al, 1974;Mariotti et al, 1979) increase in both GD and HD, and this cannot explain the decrease in LGL only in GD. It has recently been reported that anti-NK cell antibody might induce decreased NK activity in systemic lupus erythematosus (Rook et al, 1982). It is unknown, however, whether this could also be true in autoimmune thyroid diseases.…”

Section: Discussionmentioning

confidence: 99%

Decrease of Peripheral Large Granular Lymphocytes in Graves' Disease

Iwatani¹,

Amino²,

Mori³

et al. 1985

Autoimmunity and the Thyroid

View full text Add to dashboard Cite

“…Autoantibodies to NK cells have been found in the sera of patients with SLE , and inhibit the cells’ regular function . Anti‐killer immunoglobulin‐like receptor 2DL1 (KIR2DL1) and KIR2DL3 autoantibodies have been found in patients with SLE, rheumatoid arthritis (RA) and Behçet’s disease , and the receptor expression level of KIR2DL1, determined by flow cytometry analysis in patients with SLE, was found to be lower than that in healthy controls; that of KIR3DL1 was similar in both types of individuals .…”

Section: Introductionmentioning

confidence: 99%

Autoantibodies to killer cell immunoglobulin-like receptor 3DL1 in patients with systemic lupus erythematosus

Doi

Kano

Asano

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary A genetic variant of the killer immunoglobulin‐like receptor 3DL1 (KIR3DL1) has been found in patients with systemic lupus erythematosus (SLE). Herein, we investigated the presence of autoantibodies to KIR3DL1 in a cohort of patients with SLE. We tested sera from 28 patients with SLE, 11 patients with rheumatoid arthritis (RA) and 17 healthy control subjects for anti‐KIR3DL1 activity by an enzyme‐linked immunosorbent assay (ELISA) using recombinant KIR3DL1‐enhanced green fluorescent protein (EGFP) and EGFP proteins. Anti‐KIR3DL1 antibodies were detected in 22 (79%) of the 28 patients with SLE, whereas they were present in only three (27%) of the 11 patients with RA examined. Notably, 10 (91%) of the 11 samples from patients with SLE prior to therapy had anti‐KIR3DL1 antibodies. None of the samples from healthy donors were positive for the antibodies. Here, we report the presence of anti‐KIR3DL1 antibodies in the sera of patients with SLE for the first time. Anti‐KIR3DL1 autoantibodies may be involved in the pathogenesis of autoimmune diseases.

show abstract

Cytotoxic antibodies to natural killer cells in systemic lupus erythematosus

Cited by 21 publications

References 16 publications

Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases

Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases

Decrease of Peripheral Large Granular Lymphocytes in Graves' Disease

Autoantibodies to killer cell immunoglobulin-like receptor 3DL1 in patients with systemic lupus erythematosus

Contact Info

Product

Resources

About